[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors",
    "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $387.15, denoting a -1.08% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=ad9fa1bdee30591fba4c05971b124c0bbc23c9cea5f32cefcfab0b15d50937b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758149405,
      "headline": "Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors",
      "id": 136797790,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $387.15, denoting a -1.08% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=ad9fa1bdee30591fba4c05971b124c0bbc23c9cea5f32cefcfab0b15d50937b1"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=cb6f64069b6841a38c719a47aa67b946210a44c1ca0f6dd5fa2a3a171b8642d7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758127200,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "id": 136806015,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=cb6f64069b6841a38c719a47aa67b946210a44c1ca0f6dd5fa2a3a171b8642d7"
    }
  },
  {
    "ts": null,
    "headline": "2 Growth Stocks to Buy and Hold Forever",
    "summary": "Look beyond the recent headwinds these two have faced.",
    "url": "https://finnhub.io/api/news?id=a1c6412f92871cca7099b273cd545c62a85ba837ecbfb34831f4220719704a99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758121200,
      "headline": "2 Growth Stocks to Buy and Hold Forever",
      "id": 136789949,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Look beyond the recent headwinds these two have faced.",
      "url": "https://finnhub.io/api/news?id=a1c6412f92871cca7099b273cd545c62a85ba837ecbfb34831f4220719704a99"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Plunges Around 24% in Six Months: How to Play the Stock",
    "summary": "Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.",
    "url": "https://finnhub.io/api/news?id=99ba2f51880573d5173b9a96f1a667abe614fcf001016d583fd9e4fbced86415",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758119280,
      "headline": "Vertex Plunges Around 24% in Six Months: How to Play the Stock",
      "id": 136789349,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.",
      "url": "https://finnhub.io/api/news?id=99ba2f51880573d5173b9a96f1a667abe614fcf001016d583fd9e4fbced86415"
    }
  },
  {
    "ts": null,
    "headline": "How Recent FDA Approval Impacts the Valuation Story for Vertex Pharmaceuticals in 2025",
    "summary": "If you have been eyeing Vertex Pharmaceuticals and wondering whether it is the right time to buy, sell, or simply hold tight, you are far from alone. Vertex has been on a journey, sometimes up, sometimes down, which has kept investors on their toes. Over the past year, the stock fell 18.7%, a move that might make some skittish, while longer-term holders can still point to impressive gains of 36.4% over three years and 46.3% over five. Shorter-term numbers, like the -1.3% seven-day return and...",
    "url": "https://finnhub.io/api/news?id=83474d4ff78870c3cb6c0085b31ebb2e9da7a8d4c60b02ea436f7052f1ad25e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758112888,
      "headline": "How Recent FDA Approval Impacts the Valuation Story for Vertex Pharmaceuticals in 2025",
      "id": 136787636,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "If you have been eyeing Vertex Pharmaceuticals and wondering whether it is the right time to buy, sell, or simply hold tight, you are far from alone. Vertex has been on a journey, sometimes up, sometimes down, which has kept investors on their toes. Over the past year, the stock fell 18.7%, a move that might make some skittish, while longer-term holders can still point to impressive gains of 36.4% over three years and 46.3% over five. Shorter-term numbers, like the -1.3% seven-day return and...",
      "url": "https://finnhub.io/api/news?id=83474d4ff78870c3cb6c0085b31ebb2e9da7a8d4c60b02ea436f7052f1ad25e4"
    }
  }
]